Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000921895-26-000454·Avalo Therapeutics, Inc.
Schedule 13G ownership disclosure
Avalo Therapeutics, Inc.
Common Stock, $0.001 par value per share · CUSIP: 05338F306
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- BIOTECHNOLOGY VALUE FUND L P
Shares: 1,286,909.00 · Class: 6.8%
- BVF I GP LLC
Shares: 1,286,909.00 · Class: 6.8%
- BIOTECHNOLOGY VALUE FUND II LP
Shares: 500,507.00 · Class: 2.7%
- BVF II GP LLC
Shares: 500,507.00 · Class: 2.7%
- Biotechnology Value Trading Fund OS LP
Shares: 97,524.00 · Class: 0.5%
- BVF Partners OS Ltd.
Shares: 97,524.00 · Class: 0.5%
- BVF GP HOLDINGS LLC
Shares: 1,787,416.00 · Class: 9.4%
- BVF PARTNERS L P/IL
Shares: 1,904,257.00 · Class: 9.99%
- BVF INC/IL
Shares: 1,904,257.00 · Class: 9.99%
- LAMPERT MARK N
Shares: 1,904,257.00 · Class: 9.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000921895-26-000454
- Form type
- SCHEDULE 13G/A
- Filer
- Avalo Therapeutics, Inc.
- CIK
- CIK 1534120
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership